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INTRODUCTION
The increasing prevalence of neurodegenerative diseases such as Alzheimer's, Parkinson's and Amyotrophic Lateral Sclerosis (ALS) is a growing public health concern for the US population and devastating for patients and their families. By 2050, an estimation of 16 million Americans will suffer from Alzheimer's disease with total costs of $1.1 trillion (in today's dollars) [1, 2] .
Conventional approaches to treat neurodegenerative diseases are limited to managing symptoms and curbing disease progression [3] . In spite of some exciting progress in the broad biomedical research field, overall efforts in developing conventional therapeutics to ameliorate or even cure neurodegenerative diseases have had limited clinical success. CNS-directed gene therapy is a promising approach for treating neurodegenerative diseases and offers some advantages over conventional remedies, which could ultimately lead to tissue specific, long-term delivery of therapeutic agents and curative measures [4] [5] [6] [7] [8] [9] .
A significant barrier of CNS gene-delivery is the blood brain barrier (BBB), which prevents large or hydrophilic molecules such as dopamine, chemotherapeutics and viruses from passively entering the brain [10, 11] . On the other hand, rAAVs hold promise for efficient, stable, and safe gene delivery to a wide range of tissues including the CNS [4, 8, [12] [13] [14] [15] , but methods of delivery for rAAV-mediated gene transfer remain an intricate and demanding aspect of vector-based CNS gene therapy. Direct stereotactic injections of rAAVs are ideal for diseases with local CNS pathology, but cannot transduce the CNS broadly [16] . This can be accomplished by systemic rAAV delivery that utilizes the ramified capillary network of the CNS to ameliorate widespread pathologies in the CNS. Although systemic delivery of the first generation of rAAV2 to the CNS has proven to be difficult, it can be marginally improved by transient pharmacological modulation of the BBB, producing a limited CNS transduction [17] .
Recent discoveries of new clades of primate AAVs have substantially expanded potential applications of rAAVs in preclinical and clinical gene therapy [14, [18] [19] [20] [21] . Importantly, one of these novel primate serotypes, rAAV9, can achieve robust transduction of neuronal and glial cell types in the CNS of murine neonates following intravenous injections and has shown encouraging results in treating a number of CNS diseases that require early-life intervention [4, 6, 8, 15, 22] . Studies in adult animals, however, demonstrated significantly restricted entry of viral particles into the CNS and declined transduction efficiency due to the advanced BBB development [15, 23] . In searching for means to overcome this limitation, a subsequent study by our group has identified several additional rAAVs that are as or more effective as rAAV9 in transducing the neonatal CNS [22] , which motivated our selection of rAAVs for adult transduction in the current study.
A serious challenge to rAAV9-mediated systemic gene delivery to the CNS is the lack of CNSrestricted tropism and therapeutic functionality, which results in simultaneous robust transduction of peripheral tissues such as liver, heart, lung, muscle and pancreas [23] [24] [25] .
Although endogenous miRNA-regulated rAAV9 is capable of detargeting transgene expression from peripheral tissues towards CNS-restricted transgene expression in mice [26] , an expanded repertory of rAAV vectors with discriminating tropism for the CNS and a reduced affinity for peripheral tissues will be desirable to limit potential peripheral toxicity, allow for greater therapeutic control and flexibility as well as bypassing possible pre-existing immunity to rAAV9 in patient populations [27] [28] [29] .
In order to identify highly CNS tropic rAAV(s) with naturally reduced peripheral tissue tropism for systemic gene delivery to the CNS, we compared the CNS transduction efficiencies of 12 different rAAVs (rAAV 1, 2, 5, 6, 6.2, 7, 8, 9, rh.8, rh.10, rh.39 and rh.43) in 10 weeks old adult mice following systemic delivery and performed a proof-of-concept study of systemically delivered rAAVrh.10 with and without miRNA-regulated transgene expression in nonhuman primates. We report that rAAVrh.8 is a novel and superior vector, displaying strong tropism towards clinical relevant regions of the CNS with reduced dissemination to peripheral tissues in mice. We also demonstrate in a proof-of-concept study for the first time the successful CNS gene transfer by systemically delivered rAAVrh.10 and miRNA-regulated transgene expression in nonhuman primates (NHPs).
RESULTS

Seven rAAV vectors can achieve efficient global transduction of the adult mouse CNS.
To determine the transduction efficiency of each serotype after I.V. injection, we detected and quantified the EGFP signal from the coronal sections of brains and transversal sections of cervical, thoracic and lumbar spinal cords (Figs. 1-3) . Based on the density of the transduced cells (see Materials and Methods), we grouped 12 rAAVs into four groups ( Figs. 1 and 2 ; Suppl. Table 1 ). Group 1 is consisted of three vectors, rAAVrh.8, rAAVrh.10 and rAAV9. This group ranked consistently as the top three in the transduction levels in both brain and spinal cord. The only exception is the spinal cord neurons, where the top seven vectors showed similar levels of transduction ( Fig. 3G; Suppl. Fig. 1 ). Group 2 is consisted of four vectors, rAAV7, rAAV8, rAARrh.39 and rAAVrh.43. This group ranked lower than the group 1 but their overall transduction levels were still excellent. In some cases (e.g. total spinal cord and spinal cord neurons), the differences between this group and group 1 were small and insignificant (Figs. 1,   2 and 3C, G, Suppl. Tab. 1). All the group 1 and group 2 vectors transduced spinal cord motor neurons robustly (Suppl. Fig. 1 ). Group 3 is consisted of three vectors, rAAV1, rAAV6 and rAAV6.2. The transduction levels by this group were lower than groups 1 and 2. In most instances, rAAV6.2 ranked the highest and the AAV1 the lowest within this group (Figs. 1-3 , Suppl. Fig. 1 ). This group had high transduction of blood vessels (data not shown). Group 4 is consisted of two vectors, rAAV2 and rAAV5. This group had the lowest transduction levels (Figs.
1-3)
. rAAV5 transduced few or no cells as well as blood vessels in the CNS. rAAV2 transduced small populations of neurons in the dentate gyrus and the hypothalamus, and scattered astrocytes and neurons in the cortex and some ependymal cells (Data not shown). Based on these assessments, we focused our detailed analysis on the group 1 vectors and some representatives of group 2 and group 3 vectors. 
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by a semi-quantitative scoring system (see Materials and Methods) [16] . The only exception was in the spinal neurons, where the top 7 serotypes had essentially the same transduction efficiency (Fig. 3G) .
The group 1, 2 and 3 vectors transduce multiple cell types and various neuronal populations in the CNS. To identify the cell types that the vectors transduce, we first carried out morphological analysis on the CNS tissue sections stained for GFP. By high magnification microscopy we observed extensive transduction of neurons, astrocytes and oligodendrocytes in various areas of the CNS ( Figs. 3 and 4 ; Suppl. Figs. 1-3 ). For example, the group 1 vectors transduced granular cells in dentate gyrus (Fig. 4B, Suppl. Figs. 2 and 3B) , pyramidal neurons in CA2 (Fig. 4D, Suppl. Figs. 2 and 3D) , medial spiny neurons and astrocytes in striatum ( Fig.   4E ; Suppl. Figs. 2 and 3E), Purkinje neurons in cerebellum (Fig. 4 Cerebellum; Suppl. Figs. 2 and 3J), neurons and astrocytes in thalamus ( Fig. 4H; Suppl. Fig. 2 and 3H) , hypothalamus ( Fig. 4G; Suppl. Fig. 3G ), amygdala ( Fig. 4I; Suppl. Fig. 3I) , layer 3-6 of the cortex (Fig. 4 A, F; Suppl. Figs. 2 and 3 A, F) , substantia nigra (Fig. 4 SN; Suppl. Fig. 3K ), ventral tegmental area (not shown) and lateral septum (Fig. 4 LSN; Suppl. Fig. 3L ). Additionally, they also transduced oligodendrocytes in corpus callosum ( Fig. 4C; Suppl. Figs. 2 and 3C) . A similar cellular transduction pattern was also observed for group 2 and 3 vectors, albeit that the density of transduced cells was lower than group 1 vectors ( Figs. 1 and 2; Suppl. Fig. 2) . To verify the transduced cell types, we performed double fluorescence staining on the rAAVrh.8-treated CNS tissues. Using markers for specific cell types, including NeuN for neurons, GFAP for astrocytes, APC for oligodendrocytes, Iba1 for microglia and CD31 for blood vessels, we verified that EGFP was expressed in neurons, astrocytes, oligodendrocytes and blood vessels, but not in microglia (Fig. 5) . We also verified EGFP expression in several specific neuronal subpopulations, including Purkinje cells (calbindin), motor neurons (ChAT), medial spiny neurons and dopaminergic neurons (tyrosine hydroxylase) (Suppl. Fig. 5 ).
rAAVrh.8 injections result in less peripheral tissue dissemination compared to rAAV9 and rAAVrh.10. In addition to strong and widespread transduction in the CNS, we consider low peripheral tropism to be an important property of an ideal viral vector for systemically delivered and CNS-targeted gene therapy. To characterize biodistribution profiles of I.V. delivered rAAV in various tissues of the injected mice, qPCR quantification of rAAV genomes was carried out for the group 1 vectors in brain, spinal cord, lung, kidney, pancreas, skeletal muscle, heart and liver tissues (Fig. 6A) . The copy numbers of persistent rAAVrh.8 genomes were similar to those of rAAV9 and rAAVrh.10 in the brain but significantly lower than rAAV9 and rAAVrh.10 in the liver.
To assess the degree of transduction in the brain relative to the peripheral tissues, we calculated the ratios between the genome copies in the brain and those in the periphery. We did not detect a significant difference between the vectors in the group 1 probably due to a high degree of variation among the injected animals ( Fig. 6B) . Nevertheless, we observed a trend towards relatively high CNS transduction over the periphery for rAAVrh.8 compared with rAAVrh.10 and rAAV9.
Systemically delivered rAAVrh.10 transduces the motor neurons of adult marmosets. To determine CNS transduction efficiency in NHPs by I.V. injection, we conducted a proof-ofconcept experiment. We intravenously dosed two adult marmosets, one with rAAVrh.10EGFP and the other with rAAVrh.10EGFP-miR-1BS-miR-122BS3 (rAAVrh.10EGFP-miRBS). The latter vector expresses EGFP and carries three repeated copies of miRNA binding sites in its 3'-UTR for miR-1 that is abundant in heart and muscle and miR-122 that is abundant in liver [30] .
Consequently, these endogenously expressed miRNAs can bind to the transgene/EGFP mRNA in heart, skeletal muscle and liver and thus repress the transgene expression. A third marmoset was injected with rAAVrh.10EGFP intrathecally for comparison. The animals were euthanized 2 weeks after injection and the EGFP expression in both CNS and peripheral tissues were analyzed. The results of CNS transduction for the intrathecally injected monkey were published elsewhere [27] . The data for CNS transduction in two I.V. injected animals and peripheral tissue transductions in all 3 monkeys are presented below.
I.V. injection of rAAVrh.10EGFP to the one adult marmoset generated striking EGFP transduction in motor neurons throughout the entire length of the spinal cord ( Fig. 7A-F ) and oculomotor nucleus resided in the ventral midbrain ( Fig.7G-I) . Additionally, the axon fibers in the posterior horn and cuneate fasciculus at the cervical and thoracic levels robustly expressed EGFP (Suppl. Fig. 6A, C) , indicating that the neurons in the dorsal root ganglia (DRG) were well transduced at these regions. The axon fibers in the posterior horn and cuneate fascicules at the lumbar level and the neurons and astrocytes in the intermediate zone of the spinal cord also expressed EGFP, although the expression in these regions was not as strong as the ventral horns at all levels and the dorsal horns at the cervical and thoracic levels ( Fig. 7A-F The peripheral tissue transduction profiles showed differences among the three marmosets.
While all three injected animals showed little muscle transduction (data not shown), liver transduction was robust in the animal treated with I.V. rAAVrh.10EGFP (Fig. 8A ) but substantially reduced in the animal treated with I.V. rAAVrh.10EGFP-miRBS (Fig. 8C) , thus suggesting that the incorporation of the endogenous miRNA-targeting sites can de-target rAAV expression in liver. Likewise, physically restricted CNS gene delivery by intrathecal injection of rAAVrh.10EGFP remarkably limited EGFP transduction in the liver (Fig. 8C) despite its robust transduction of motor neurons and dorsal root ganglion neurons throughout the spinal cord [27] .
All three animals showed poor heart transduction (data not shown), thus we could not assess whether a particular treatment method reduced heart transduction. Interestingly, regardless of miRNA regulation or different routes of vector administration, the adrenal cortex expressed EGFP robustly in all 3 marmosets (Fig. 8B, D, F) .
DISCUSSION
It is well documented that intravascular delivered rAAVs are excellent vectors for CNS gene therapy in neonatal animals [4, 15, 31] . However, earlier studies in adult mice by I.V. injected rAAVs generated limited CNS transduction due to the advanced BBB development in adult animal models [17, 22, 32 ]. Here we demonstrate that several rAAVs are capable of crossing the BBB efficiently following I.V injection by using a semi-quantitative scoring system for a quick assessment of cell transduction efficiency. We opted for this method to evaluate rAAV transduction efficiency since it has been successfully applied and published previously [22, 33] .
However, we recognize that the semi-quantitative scoring system has disadvantages in assessing absolute differences between serotypes. Thus, to differentiate the fine points among the rAAV serotypes, more extensive quantitative analyses will be needed. Another caveat of this study is the number of animals per group (n=3). Although, 3-4 animals per group are widely used to evaluate the transduction efficiency of rAAV [16, 17, 23, 25, 33] , animal-to-animal variations even with inbred animals might influence the final results. To minimize this possibility, we injected male mice only. Despite the limitations of the method, the semi-quantitative characterization provides useful reference points for the future use of these AAV serotypes for I.V. delivery.
Of all the rAAV serotypes tested, the most robust in crossing the BBB are the group 1 vectors consisted of rAAV8, rh.10 and 9 ( Figs. 1-3 ; Suppl. Table 1 ). Although less robust than the group 1 vectors, the group 2 vectors, consisted of rAAV8, 7, rh.43 and rh.39, also show strong capability of transducing cells in broad CNS areas following I.V. injection. These results suggest that the group1 and group 2 vectors achieve similar results and expand the repertoire that may be used as alternative vectors to deliver therapeutic genes for treating CNS diseases via I.V.
injection. It is worthwhile to point out that the grouping should not be interpreted as if there are absolute boundaries between the groups, but rather, it is used as a means to facilitate the description of the large number of AAV serotypes tested and to provide a useful guide for selecting the most suitable vectors in future experimentation.
Among the top vectors, a particular standout is the rAAVrh.8. With its global and robust transduction of the CNS cells, rAAVrh.8 consistently ranked first in broad CNS areas and in different cell populations (Fig. 3) . A particularly attractive feature for rAAVrh.8 is its naturally lower peripheral tissue dissemination than other vectors, particularly in the liver (Fig. 6) , which enhances the safety profile of systemic gene delivery to the CNS. These qualities suggest that rAAVrh.8 is a top candidate vector for treatment of the CNS diseases that afflict broad areas of the CNS. For example, the broad transduction of the forebrain areas is a property that can be applied to treat Alzheimer's disease, which causes neurodegeneration in forebrain areas [34] .
Similarly, the robust transduction throughout the spinal cord, brainstem and cortex are characteristics desirable for treatment of amyotrophic lateral sclerosis (ALS) and Canavan's disease. ALS causes motor neuron degeneration in cortex, brainstem and spinal cord [35] .
Canavan's disease causes neurodegeneration throughout the CNS due to deficiency in aspartoacylase [4] . Of note, rAAV9 displays similar transduction qualities by I.V. injection in the spinal cord of adult mice, as reported previously [36] , although it ranked slightly below the performance of rAAVrh.8 in side-by-side comparisons ( Fig. 2 and 3) . However, a direct comparison with previously published data is often complicated due to possible differences in vector production, dose and quantification methods [36] .
The robust transduction of the CNS cells following I.V. injection is a surprising but useful character of some rAAV vectors. How these rAAVs cross the BBB remains elusive [32, 37, 38] . Nevertheless, our results suggest two possible routes for the rAAVs to enter and transduce the CNS. First, the rAAVs might cross the BBB by exploiting the fenestrated capillary vessels of circumventricular organs [39] . This is supported by the fact that we consistently observed strong EGFP expression in or near circumventricular organs such as the choroid plexus ( Fig. 1 ; Suppl. and rAAVrh.10 panels in Suppl. Fig. 2) . Additionally, we also noticed the intense EGFP expression in neurons and glia near the 3 rd ventricle (e.g. the area between the corpus callosum and the third ventricle in the AAVrh. 8 panel in Suppl. Fig. 2) . The second possibility could be the direct transcytosis of rAAVs via endothelia [38] , which represent the most inner layer of blood vessels. Perivascular astrocytes have been shown to regulate the tightness and exchange of molecules across the BBB [11, 40, 41] . Therefore, the presence of intensely stained blood vessels and their surrounding astrocytes suggests that rAAVs use this second route of entry into the CNS (Fig. 4 and Suppl. Figs. 2 and 3) . Further studies will be needed to understand the transduction mechanism of rAAVs. Parkinson's and Huntington's diseases [24, [42] [43] [44] . Previously, systemically delivered rAAV9 has been evaluated in NHP animals for CNS targeting with promising results [16] [17] [18] . In our proof-of-concept study, we systemically delivered rAAVrh.10 for the first time to the CNS of the NHP marmosets and noticed some unique characteristics in the resulting transduction pattern.
I.V. injection of rAAVrh.10 robustly transduced the motor neurons in the spinal motor column
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© 2014 The American Society of Gene & Cell Therapy. All rights reserved and brainstem but scattered neurons and astrocytes in the forebrain and cerebellum ( Fig. 7; Suppl. Figs. 6-11). These findings contrast with what was reported for intravascular delivered rAAV9 in cynomologus macaques, which transduced mostly astrocytes in the brain [15, 23, 45] .
The causes for these differences are not clear but could be attributed to differences in the vector biology between rAAV9 and rAAVrh.10, animal species (i.e. cynomologus versus marmoset)
and age, etc. In any case, the data generated from a single marmoset with known high animalto-animal variations in outbred NHP animals is a major caveat of our NHP study. More extensive studies will be required to confirm the vector biology of rAAVrh.10, and perhaps more importantly, to assess the performance of the rAAVrh.8 vector in marmosets or other NHP species.
In this study, we also attempted translating the design of miRNA-regulated transgene expression from murine to a NHP model. Endogenous miRNA-mediated posttranscriptional regulation of transgene expression is an attractive method to detarget rAAV transduction from non-target tissues and cell types and will be desirable to prevent potential peripheral transgene toxicity as well as transgene directed immune response in peripheral tissue [29] . This strategy is effective in mice as we and others have demonstrated previously [26, [46] [47] [48] . Considering the conservation of miRNA sequences between human, marmoset and mouse, particularly the high homology of mir-122 and mir-1 (about 99%) [49] , we tested this design in marmoset, which is the first application of this kind in rAAV gene transfer in primates. Indeed, our data demonstrated the effectiveness in detargeting of rAAVrh.10 expression from major peripheral tissues e.g. liver. It is rather interesting that rAAVrh.10 robustly transduced adrenal gland regardless of miRNA-detargeting and route of administration, which may hold promise for some clinical applications such Addison's disease [50] . However, the CNS transduction of miRNAregulated vectors seemed to be underwhelming as compared to the vector without miRNA binding sites. Again, it is difficult to draw a firm conclusion from an experiment that includes only 
MATERIALS AND METHODS
Vector cloning and production. The structure of the EGFP reporter vector genome was the 
Semi-quantitative analysis of EGFP positive cells transduced by rAAVs.
We reviewed clinically relevant regions including cortex, corpus callosum, hippocampus, striatum, cerebellum, thalamus and medulla of the brain as well as cervical, thoracic and lumbar sections of the spinal cord (Figs. 1, 2 and 4; Suppl. Figs. 1, 2 and 3) . To provide a semi-quantitative measure of the amount and type of cells that were transduced by rAAVs in the CNS, we used a previously described [22] scoring system that was originally developed by Cearley et al. [33] . Briefly, the Sections of rAAVrh.8-transduced cells were stained for different cell markers to confirm the cell identity (see Fig. 5 ). Statistical analysis was performed using one-way ANOVA test for comparison of semi-quantitative scores as well as biodistribution data.
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The CNS tissues were isolated, fixed, sectioned, and stained for EGFP as described in Methods 
